Mangalore: ARMC IVF completes a year of functioning

[email protected] (CD Network)
January 24, 2014
ARMC_Press_24

Mangalore, Jan 24: ARMC IVF, a unit of Repro Health Care Mangalore Pvt Ltd cpmpleted a year of functioning with the birth of first Intracytoplasmic Morphologically selected Sperm Injection (IMSI) baby in Dakshina Kannada on October 27 .

Addressing the media persons on Friday, Dr. Raghavendra Prasad, executive director of the centre said that the IMSI treatment by the organisation used for fertility in male and female in the district has seen success through its first baby.

“Treatment is a special practice in which the sperms are seen under a special microscope with a high magnification so that every part of sperm can be seen in detail. Also the best sperms are selected and injected inside the female ovaries. This gives a high fertilization rate and better quality of embryos, which results in chances of pregnancy rate,” he briefed.

The expenses of the treatment for couple would start from Rs 1.5 lakh. It provides every treatment for the couples who are unable to conceive by natural means. Centre has expert fertility consultants, embryologists, andrologists, counsellors and technicians, he said.

Dr. Gaurav Gujarathi, chief IVF specialist said the treatment has 30 to 40 per cent of success rate. Treatment will take minimum of 45 days of time duration, he said.

Comments

Best Fertility…
 - 
Tuesday, 19 Nov 2019

Thank you for the useful article. You have given very good information.

best fertility…
 - 
Monday, 5 Aug 2019

Very good information about the IVF. thank you.

treatment for …
 - 
Tuesday, 2 Jul 2019

Thank you for given information about the IVF. 

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 28,2020

Bengaluru, Mar 28: Sun Tsu, in 'The Art of War' speaks of a skilful general who can subdue his enemy without any fighting. This constitutes the ultimate triumph which is referred to as stratagem. Today, we would need one such when we are faced with the '21-day corona challenge' for India.
Nearly four weeks back, Dr Jyothsna Rao, Dr Gururaj Rao and I sat across the OPD in the afternoon at HCG Bengaluru discussing our ongoing cancer immunology research. While on this topic, we drifted into the discussion on the coronavirus. During this engaging discussion, we wondered the similarity of the enigma between the virus and cancer. I paused to ask Dr Jyothsna and Dr Guru - how we wish we could do something against this virus.
Dr Jyothsna is a PhD from NCBS and had worked under Dr Ralph Steinman, physician and researcher from Rockefeller University, who won the Nobel Prize for his discovery of the dendritic cell and its role in adaptive immunity in 2011. Dr Gururaj is a molecular and cell biologist who did his PhD at the Chapel Hill, University of North Carolina and is the Director of iCrest.
Jyothsna while hearing our perplexing conversation on the covid intervened, "Yes, surely. I think we should take a break from cancer and focus on the innate and adaptive immunity role in COVID-19."
Thus began this sincere attempt to relook the human immune system from the eyes of the COVID-19.
We have 10 types of immune cells at the least which are widely dispersed in millions across the body. When our body is invaded by a foreign organism (bacteria, fungi or virus), these cells work with each other to destroy the invader.
Now, the question is - how do the immune cells talk to each other? They use small-molecule substances called cytokines (cyto means cells; kine means movement). There are many cytokines that are involved in work on the immune system. The most relevant for viruses are interferons.
Interferons (IFN) as the name reflects have an ability to interfere with the viral activity and stop their multiplication. These specialised signal proteins are released by our cells in response to a viral attack to forewarn other cells. They help build the antiviral proteins within the cells to kill the virus as it tries to invade the new cells.
Historically, interferons are a group of cytokines known to be potent antiviral agents against viruses and a hallmark cytokine induced by the host upon viral infections. Interferons possess unique immunoregulatory activities and are signature cytokines released by (TH1) T immune cells, which are crucial in viral infections.
As the outbreak of COVID-19 grapples us, an urgent need for finding strategies to combat the virus is growing. Coronaviruses (CoVs) are a group of RNA viruses. In patients infected with coronavirus, it was indicated that the activation of the IFN does not occur until 48 hours post-infection. Thus the delayed IFN-related antiviral response by the healthy cells leads to coronavirus evade the immune response.
Numerous studies have presented the success in defeating CoVs by the direct administration of IFNs. In a combination as a concoction, it was shown to synergistically inhibit the virus replication in vitro.
Moreover, it is understood that the earlier induction of IFNs in children although they have a less developed immune system could be the reason behind the children being least affected.
The key to success in reducing the disease fatality might be the stimulation of the immune responses to trigger IFN production at the very early stages of the disease, which might be done through the administration of IFN. Despite the evidence for the efficacy of IFNs in treating CoV-induced infections, the proper dosing and ideal timing for such interventions needs to be verified in clinical trials.
For the later stages of the diseases in advance stages where patients are on ventilator and have developed respiratory distress, we propose to utilise the mesenchymal cells derived from donor bone marrow that have been known to treat acute respiratory syndrome. Mesenchymal cells are known to possess anti-inflammatory activity and thus used often in autoimmune diseases.
With this scientific background, we have activated T cells from healthy donors, in a cGMP facility at iCrest - HCG hospital with an enriched cocktail of cytokines rich in Interferons. Injections of this cocktail we believe will result in a surge of cytokines in the body of the infected person and will boost his ability to fight the virus in the early phases. We are in the initial phases of this study and hope to be ready in the coming weeks with meaningful data on its potential utility.
Currently, it awaits government approvals (Union and state) and we have applied to central drugs authority for their initial evaluation and further directions.
As my Guru often expounded the philosophy of 'Seva' - the goal of education is knowledge, the end goal of knowledge is service. In this attempt to serve our fellow humans at this brink of unprecedented crisis, medical fraternity stands with you and promises to do our best for your safety.
We assure to exhaust every bit of our spirit in this fight against coronavirus. We have lost the sight of shores and travelled thus far, but that is the mandatory first step to cross the ocean. Are we going to succeed in this battle, is something only time will answer. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 16,2020

Bengaluru, Apr 16: Karnataka Chief Minister BS Yediyurappa on Thursday inaugurated a mobile Covid-19 testing booth in Bengaluru.

These mobile booths will be used in all wards of Bengaluru to collect samples of those suspected to be infected.

According to information available on the website of Ministry of Health and Family Welfare, as of Thursday, 4:00 PM, 279 coronavirus cases have been reported from the state, with 80 cured/discharged/migrated and 12 deaths.

India's coronavirus tally is at 12,380 cases, said the Union Ministry of Health and Family Welfare on Thursday.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 11,2020

Bengaluru, Jan 11: Scholar and writer M Chidanadamurthy passed away at a private hospital here on Saturday.

He was 88 and is survived by wife, son and daughter.
He was a well-known scholar in Karnataka specialising in the history of Kannada language and ancient Karnataka.

He was also known for his campaign to conserve the monuments Hampi and to secure classical language status to Kannada Language. Murthy has also articulated that uniform civil code and an anti-conversion law must be enacted by the Government in India.

Murthy was the head of the department of Kannada Bangalore University. He was also associated with Kannada Shakti Kendra. As a historian most of Murthy's work has focused on scientific study of the Kannada Inscriptions.

He has attempted to contextualise inscriptions in their socio cultural setup. He has produced many books on the history of Kannada language and Karnataka. He has guided many research students.

Murthy was recipient of Rajayothsava, Sathiya Academy Award , Papama award and Alava’s Nudisiri award.
His mortal remains were kept at his residence for his fellow mates and relatives.

Several dignatories like B S Yediyurappa, S L Bhyrappa, S Suresh Kumar, V Somanna expressed their condolences to the veteran's death.

The final rituals will be held on Sunday with state honour.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.